Category: Pfizer
Industrial cybersecurity startup Claroty raises $140M in pre-IPO funding round
Claroty, an industrial cybersecurity company that helps customers protect and manage their Internet of Things (IoT) and operational technology (OT) assets, has raised $140 million in its latest, and potentially last round of funding. With the new round of Series D funding, co-led by Bessemer Venture and 40 North, the…
Read More
Johnson & Johnson’s COVID-19 vaccine is 85% effective against severe cases, and 66% effective overall per trial data
Another COVID-19 vaccine is almost ready to begin being distributed – a single-shot inoculation made by Johnson & Johnson’s Janssen pharmaceutical subsidiary. The company just released an efficacy report based on data from its Phase 3 trial, which found that the new vaccine is 66% effective overall in preventing moderate…
Read More
FDA authorizes Moderna’s COVID-19 vaccine for emergency use
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine, as expected after an independent panel commissioned by the administration recommended its approval earlier this week. This is the second vaccine now authorized for use in the U.S. under EUA, after the…
Read More
FDA grants emergency use authorization for Pfizer’s COVID-19 vaccine, distribution to begin within days
The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for the COVID-19 vaccine developed by Pfizer and its partner BioNTech, the New York Times first reported on Friday night, and later supported by The Wall Street Journal. This EUA follows a recommendation by an independent panel…
Read More
FDA panel recommends approving Pfizer’s COVID-19 vaccine emergency use authorization
An independent panel of experts has recommended the Food and Drug Administration (FDA) approve an official Emergency Use Authorization (EUA) for the Pfizer and BioNTech COVID-19 vaccine. This means that it’s one step closer to beginning to be administered to people in special circumstances — including for front-line healthcare workers…
Read More
Moderna claims 94% efficacy for COVID-19 vaccine, will ask FDA for emergency use authorization today
Drugmaker Moderna has completed its initial efficacy analysis of its COVID-19 vaccine from the drug’s Phase 3 clinical study, and determined that it was 94.1% effective in preventing people from contracting COVID-19 across 196 confirmed cases from among 30,000 participants in the study. Moderna also found that it was 100%…
Read More